Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：73
|
作者：
Boucau, Julie [1 ]
Uddin, Rockib [2 ]
Marino, Caitlin [1 ]
Regan, James [3 ]
Flynn, James P. [3 ]
Choudhary, Manish C. [3 ,4 ]
Chen, Geoffrey [2 ]
Stuckwisch, Ashley M. [2 ]
Mathews, Josh [2 ]
Liew, May Y. [2 ]
Singh, Arshdeep [2 ]
Reynolds, Zahra [2 ]
Iyer, Surabhi L. [2 ]
Chamberlin, Grace C. [2 ]
Vyas, Tammy D. [2 ]
Vyas, Jatin M. [2 ,4 ]
Turbett, Sarah E. [2 ]
Li, Jonathan Z. [3 ,4 ]
Lemieux, Jacob E. [2 ,4 ,5 ]
Barczak, Amy K. [1 ,2 ,4 ]
Siedner, Mark J. [2 ,4 ]
机构：
[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02215 USA
[5] Broad Inst, Cambridge, MA 02138 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期
关键词：
COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;
D O I：
10.1093/cid/ciac512
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
引用
收藏
页码：E526 / E529
页数：4
相关论文
共 50 条
  • [31] Delayed COVID-19 rebound following nirmatrelvir/ritonavir treatment in B-cell-depleted patients
    Schminke, Louisa
    Fleck, Martin
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (02) : 396 - 397
  • [32] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 Response
    Wan, Eric Yuk Fai
    Yan, Vincent Ka Chun
    Mok, Anna Hoi Ying
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10) : eL230265
  • [33] The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19
    Liu, Ting-Hui
    Wu, Jheng-Yan
    Huang, Po-Yu
    Tsai, Ya-Wen
    Lai, Chih-Cheng
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (07)
  • [34] Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
    Dormuth, Colin R.
    Kim, Jason D.
    Fisher, Anat
    Piszczek, Jolanta
    Kuo, I. Fan
    JAMA NETWORK OPEN, 2023, 6 (10) : E2336678
  • [35] Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
    Reactions Weekly, 2022, 1900 (1) : 4 - 4
  • [36] Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019
    Park, Hailey J.
    Tan, Sophia T.
    Leon, Tomas M.
    Jain, Seema
    Schechter, Robert
    Lo, Nathan C.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (09):
  • [37] Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
    Gao, Yuan
    Luo, Zujin
    Ren, Shan
    Duan, Zhonghui
    Han, Ying
    Liu, Huihang
    Gao, Ziwen
    Zhang, Xinyu
    Hu, Zhongjie
    Ma, Yingmin
    JOURNAL OF INFECTION, 2023, 86 (06) : E158 - E160
  • [38] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [39] Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study
    Kane, Anna M.
    Keenan, Erica M.
    Lee, Kasheng
    Hartkopf, Katherine J.
    Ludwig, Trisha A.
    Trapskin, Philip J.
    Vanderloo, Joshua P.
    Schulz, Lucas T.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (01): : 29 - 33
  • [40] The Coronavirus Disease 2019 (COVID-19) Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
    Pandit, Jay A.
    Radin, Jennifer M.
    Chiang, Danielle C.
    Spencer, Emily G.
    Pawelek, Jeff B.
    Diwan, Mira
    Roumani, Leila
    Mina, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (01) : 25 - 31
12345